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Abstract
Background: There is growing evidence that equine papillomavirus type 2 (EcPV2) infection is causally associated
with the development of equine genital squamous cell carcinomas (SCCs). Early stages of disease present clinically
as plaques or wart-like lesions which can gradually progress to tumoural lesions. Histologically these lesions are
inconsistently described as benign hyperplasia, papilloma, penile intraepithelial neoplasia (PIN), carcinoma in situ
(CIS) or SCC. Guidelines for histological classification of early SCC precursor lesions are not precisely defined, leading
to potential misdiagnosis. The aim of this study was to identify histologic criteria and diagnostic markers allowing
for a more accurate diagnosis of EcPV2-associated equine penile lesions.
Results: A total of 61 archived equine penile lesions were histologically re-assessed and classified as benign
hyperplasia, papilloma, CIS or SCC. From these, 19 representative lesions and adjacent normal skin were
comparatively analysed for the presence of EcPV2 DNA and transcripts using PCR and RNA in situ hybridisation
(RISH). All lesional samples were positive by EcPV2 PCR and RISH, while adjacent normal skin was negative. RISH
analysis yielded signal distribution patterns that allowed distinction of early (hyperplasia, papilloma) from late stage
lesions (CIS, SCC). Subsequently, the 19 lesions were further assessed for expression of p53, Ki67, MCM7 and MMP1
by immunohistochemistry (IHC). All four proteins were expressed in both normal and lesional tissue. However, p53
expression was up-regulated in basal keratinocyte layers of papillomas, CIS and SCCs, as well as in upper
keratinocyte layers of CIS and SCCs. MCM7 expression was only up-regulated in upper proliferating keratinocyte
layers of papillomas, CIS and SCCs.
Conclusion: This study proposes combining a refined histological protocol for analysis of equine penile lesions
with PCR- and/or RISH based EcPV2-screening and p53/MCM7 IHC to more accurately determine the type of lesion.
This may help to guide the choice of optimum treatment strategy, especially at early stages of disease.
Keywords: Equine papillomavirus type 2 (EcPV2), Squamous cell carcinoma (SCC), Papilloma, Benign hyperplasia,
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Background
Papillomaviruses (PVs) are a family of small viruses con-
sisting of an icosahedral capsid harbouring a relatively
short (≈8 kbp) and circular dsDNA genome. The latter
contains ORFs for regulatory and capsid proteins, and
importantly, for two to three oncoproteins, i.e. E6, E7,
and frequently E5. PVs are usually host-specific and have
a pronounced tropism for cutaneous and mucosal kerati-
nocytes [1]. From the more than 200 human PV (HPV)
types known today, at least 15 types have been recog-
nized as carcinogenic viruses and thus are designated as
high-risk HPVs (hrHPVs). Infection of humans with
these types is responsible for nearly 100% of cervical
cancers, about 50% of anogenital squamous cell carcin-
omas (SCCs) and 25% of head and neck SCCs [2].
Equine papillomavirus type 2 (EcPV2) was first identi-
fied from cases of equine genital carcinoma in situ (CIS)
and penile SCCs in 2008, and its genome was fully charac-
terized [3]. Since then, ample evidence has accumulated
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that EcPV2 infection is aetiologically associated with the
development of equine genital SCCs [4].
SCCs arise from cutaneous and mucosal keratino-
cytes. In their initial stages, lesions may present either
as whitish plaques or as exophytic wart-like lesions/
papillomas with a cauliflower-like appearance. These
may gradually progress to cancerous lesions like lo-
cally aggressive CIS and finally to invasive SCCs [5, 6].
The EcPV2 genome has been shown to reside in up to
100% of early and late lesions in an episomal and/or
integrated form [4, 7, 8]. In a subset of lesions, infec-
tion also appears to be productive, as evidenced by
immunocapture PCR-mediated detection of virion-like
structures [7]. Importantly, EcPV2 transcribes its two
oncogenes E6 and E7 at all stages of disease, which
strengthens the evidence for an active involvement of
this virus in progression of benign lesions to malig-
nant neoplasms [4, 7, 8]. Given the presumed papillo-
maviral aetiology of equine genital lesions and their
high potential for malignant transformation and me-
tastasis, selection of the most appropriate therapeutic
strategy and its outcome largely depends on early and
accurate tumour diagnosis. In conformity with a grad-
ing system employed in human medicine [9], a system
for the grading of equine penile SCCs has already been
proposed in 2011 [10]. However, implementation of
this system is partly hampered by the fact that the
histological features of equine genital SCC precursor
lesions are not clearly defined currently, potentially
leading to misdiagnosis. In human oncology, difficulty
in distinguishing hrHPV-induced benign lesions from
more progressive lesions [11] has led to the establish-
ment of more precise diagnostic criteria that rely not
only on histological examination, but also on the
screening of neoplastic tissue for HPV infection and
expression of selected tumour markers [12, 13]. Such
criteria have yet to be established for accurate diagno-
sis of EcPV2-associated equine tumours.
In human oncology, tumour suppressor protein p53 and
cell proliferation-associated protein Ki67 are well estab-
lished markers that allow for distinction between the differ-
ent stages of cervical neoplasia [13]. Mini-chromosome
maintenance proteins (MCMs) are over-expressed in high-
grade human cervical lesions and are routinely used as sur-
rogate markers of hrHPV oncoprotein activity [14]. Matrix
metalloproteinases (MMPs) have a crucial role in both
HPV-unrelated and hrHPV-driven tumour cell migration
and invasion in that they orchestrate the degradation of the
extracellular matrix and basement membranes [15, 16]. In
the veterinary literature, overexpression of MMP1 in associ-
ation with infiltrative growth has been reported for bovine
papillomavirus type 1-induced equine sarcoids [17, 18], and
canine oral melanoma [19]. On these grounds, the hypoth-
esis of this study is that EcPV2 presence and transcription
in concert with over-expression of some or all of these
marker proteins could be indicative of progressive behav-
iour of EcPV2-associated equine penile lesions. To test this
hypothesis, 61 archived equine penile lesions were first re-
assessed on the basis of a refined histopathological protocol.
Then 19 representative penile lesions were subjected to fur-
ther analyses, i.e. screening for EcPV2 infection and tran-
scription, and expression of p53, Ki67, MCM7 and MMP1.
Results
Histological criteria for lesion classification as benign
hyperplasia, papilloma, CIS or SCC
Equine penile lesions (n = 61) were retrieved from tissue
archives of the Vetsuisse Faculties of Zurich and Bern,
Switzerland. According to available records, lesions were
grossly diagnosed as generalized hyperplasia (Fig. 1a, c
and d), depigmented plaques (Fig. 1a and b), wart-like
(Fig. 1b and c), ulcerative (Fig. 1c), or tumoural lesions
(Fig. 1d), based on their clinical appearance (Table 1).
Histologically, the different lesions were diagnosed as
benign hyperplasia, papilloma, CIS or SCC. Following
histological re-assessment of the 61 tumour sections, 19
representative lesions (6 hyperplasias, 5 papillomas, 3
CIS and 5 SCCs) were subjected to down-stream analysis
(Tables 1 and 2). The following criteria were used for
histological classification and the representative lesions
were classified as follows:
Lesions were diagnosed as benign hyperplastic lesions
when displaying thickening of the epithelium with or-
derly maturation and formation of broad rete ridges
(Fig. 2a, b and Additional file 1: Figure S1). Six cases
were included, all with a sharp transition from the nor-
mal to the hyperplastic epithelium. Hyperplastic lesions
were evaluated for the presence of koilocyte-like cells
typically presenting as swollen keratinocytes with a pale
blue cytoplasm with or without intracytoplasmic dark
blue granules (keratohyalin granules) and a normal or
pyknotic nucleus (Fig. 2b). Two hyperplasias (case num-
ber (#) 15, #16) exhibited low numbers of koilocyte-like
cells (a maximum of 5 at low magnification (10x object-
ive)), two cases (#17, #19) contained moderate numbers
(between 6 and 10) and another numerous (more than
10) koilocyte-like cells (#14). All six cases exhibited de-
pigmentation, and focal to moderately extended areas
with crowding of basal cells were observed. Keratin pearl
formation within the hyperplastic epithelium was
present in two cases (#15, #18).
Lesions were classified as papillomas when showing
finger-like projections of moderately hyperplastic, usu-
ally mildly hyperkeratotic stratified squamous epithe-
lium with normal differentiation and thin central cores
of connective tissue (Fig. 2a, b and Additional file 1:
Figure S1). Five cases all showing typical features were
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included. In one of these cases low to moderate num-
bers of koilocyte-like cells were present (#11).
Diagnosis of CIS was made in cases where transepithe-
lial and abnormal epithelial maturation, increased vari-
ability of keratinocytes, and mitotic figures in the
suprabasal region were noted (Fig. 2a, b and Additional
file 1: Figure S1). None of the three included cases con-
tained koilocyte-like cells. One had extensive basaloid
differentiation of the keratinocytes (#8) and two had
intraepithelial keratin pearl formation (#6, #8) (Fig. 2a).
There were small areas with focal disruption of the base-
ment membrane suspected to represent a microinvasion
in two cases (#6, #7).
Lesions were classified as SCCs when they consisted of
infiltrative islands and trabeculae of squamous epithelial
cells with or without keratinization, originating from the
epithelium and infiltrating the underlying dermal tissue
(Figs. 2a, b and Additional file 1: Figure S1). In two
cases, depth of infiltration was limited (less than 0.5 cm)
and, therefore, these were classified as early infiltrative
(#4, #5). All SCCs were mainly moderately differentiated,
exhibiting keratin pearl formation, moderate nuclear and
cellular pleomorphism, and obvious mitotic figures ran-
ging from 10 to 30 per 10 high power fields. In four cases
(#1, #3, #4, #5) histological examination revealed very
poorly differentiated areas without keratinization located
Fig. 1 EcPV2 associated gross lesions. Representative images of EcPV2 associated gross lesions: a.) Depigmented plaques and hyperplastic
epithelium of the penis shaft, developing up to the glans penis are visible. Histologically these lesions were diagnosed as benign hyperplasia
(#19). b Two depigmented plaques can be seen on the penis shaft (white arrow) and one on the glans penis, where a small wart-like lesion
(black arrow) is also visible, which was histologically diagnosed as papilloma. The depigmented plaques on the shaft (white arrow) were
diagnosed as carcinoma in situ (#6). c The whole penis has depigmented thickened epithelium. Two wart-like lesions are also visible (black
arrows), which were histologically diagnosed as papillomas (#13). On the penis shaft there is a small ulcerated area (white arrow), which is the
second recurrence of a surgically removed SCC. Histologically this lesion was classified as early SCC (#5). Both lesions of this horse were included
in this study, listed as separate cases. d The whole penis shows depigmented and thickened epithelium. There is a massive proliferation/mass on
the glans penis. Histologically this tumoural lesion was diagnosed as SCC (#3)
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primarily at the tumour front. Therefore these cases
were classified as grade 3, and one case (#2) as grade 2,
corresponding to Van den Top 2015 [20]. Vascular inva-
sion was detected in two cases (#2, #3). Hyperplasia of
penile epithelium was always present adjacent to the
SCC, and in two cases moderate to high numbers of
koilocyte-like cells were observed within the hyperplastic
areas.
Depigmented plaques and wart-like lesions are not
always benign
The mean age of the horses in this study is 17 years with
61% of the horses being ponies or small horses with a
high proportion of Icelandic horses (28%) (Table 1). The
histological diagnosis did not always correlate with the
clinical appearance of the lesions. Benign hyperplasia
was usually described clinically as depigmented plaques,
plaque-like lesions or generalized hyperplasia of the
penis. The clinical description for papillomas was usually
wart-like lesions of different size, but was in one case
also described as tumoural lesion. CIS cannot be distin-
guished from benign lesions from the clinical point of
view. They can present as depigmented plaques (like
benign hyperplasias) or wart-like lesions (like papillo-
mas). SCCs are usually described as tumoural or ulcera-
tive lesions, but a depigmented wart-like lesion may
already be a SCC (Table 1). In conclusion, benign and
malignant lesions cannot be reliably distinguished clinic-
ally but only by histological examination.
EcPV2 DNA and oncogene transcripts were present in
100% of lesions tested
In the first step, DNA extracted from the 19 penile le-
sions (i.e. 6 benign hyperplasias, 5 papillomas, 3 CIS,
and 5 SCCs) were assessed for the presence of EcPV2
DNA by specific EcPV2 E6 PCR. This yielded a positive
result in all cases. To check for potential co-infection
and the presence of other papillomaviruses associated
with genital lesions in horses, broad-range PV PCRs
were performed using CP4/5 and Fap59/64. No other
PVs were detectable within these lesions. In the next
step, lesions were tested for the presence and cellular
localization of EcPV2 E6 and E7 transcripts using RISH.
All 19 lesions (100%) were positive for viral E6 and E7
mRNA, while perilesional normal skin if present on the
same slides, was negative (Table 2, Fig. 2c and d). RISH
Table 1 Sample specification
Sample Breed Age Clinical Description Histological
Diagnosis
1 Pony 18 preputial tumoural lesion, 5 cm diameter SCC
2 German riding
horse
20 multiple depigmented wart-like lesions glans penis SCC
3 Haflinger 16 generalized hyperplasia of the penis with tumoural changes on the glans penis, 10 cm
diameter
SCC
4 Welsh Pony 22 generalized hyperplasia of the penis with tumoural changes on the glans penis, 5 cm
diameter
SCC early
5 Icelandic horse 17 generalized hyperplasia and ulcerative lesions on the penis shaft SCC early
6 Icelandic horse 22 multiple depigmented plaques glans penis and penis shaft with wart-like lesion on glans
penis
CIS
7 Bavarian
Warmblood
16 multiple depigmented plaques and tumoural lesion penis CIS
8 Icelandic horse 16 multiple wart-like lesions penis shaft CIS
9 n.a. 13 wart-like lesion penis shaft Papilloma
10 Icelandic horse 20 tumoural lesion penis 2 cm diameter Papilloma
11 Lusitano 14 multiple large wart-like lesions Papilloma
12 Shetland Pony 20 multiple large wart-like lesions penis Papilloma
13 Icelandic horse 17 generalized hyperplasia and wart-like lesions Papilloma
14 n.a. 8 depigmented plaques penis Hyperplasia
15 Welsh Pony 13 depigmented plaques penis Hyperplasia
16 Lusitano 15 depigmented plaques penis Hyperplasia
17 Freiberger 13 generalized hyperplasia and ulcerative lesions penis Hyperplasia
18 Irish Warmblood 14 plaque-like lesion penis shaft Hyperplasia
19 Icelandic horse 22 plaque-like lesions penis shaft and glans Hyperplasia
n.a. not available, clinical description: the parts of the lesions, which were further assessed histologically in this study, are marked in bold
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yielded two different signal distribution patterns: a
finely scattered granular signal (GS) throughout the nu-
cleus and cytoplasm, or, alternatively, an intense diffuse
nuclear signal (DNS). Abundant GS was detectable in
all penile lesions at high magnification (40x objective),
while adjacent perilesional tissue did not contain signal
(Table 2, Fig. 2c and d). In two CIS lesions, however,
the GS was scarce. DNS, when present, was easily vis-
ible at low magnification (4x objective) and predomin-
antly in the upper keratinocyte layers. A DNS was
frequently detected in hyperplasias and papillomas, but
rarely detectable in SCCs and CIS, and absent in perile-
sional tissue (Table 2, Fig. 2c, d and Additional file 2:
Figure S2). As a consequence, the difference between
the amount of DNS in benign (hyperplasia and papil-
loma) and malignant (CIS and SCC) lesions was signifi-
cant (two-tailed Mann Whitney test p = 0.0011).
Observed virally induced cytopathic changes, i.e. koilo-
cyte formation, corresponded partially with DNS
localization (Fig. 2, Additional file 1: Figure S1 and
Additional file 2: Figure S2).
Upper keratinocyte layers of CIS and SCCs exhibit up-
regulated p53 and MCM7 expression
Following PCR and RISH screening, the 19 penile lesions
were assessed for expression of the surrogate markers
for proliferation and cancer p53, Ki67, MCM7, and
MMP1 using IHC.
All lesions and adjacent normal tissue were positive
for nuclear p53 immunostaining. In almost all SCCs,
CIS and papillomas > 90% of basal cells expressed p53.
In most hyperplasias and normal adjacent tissue, < 50%
of basal cells were positive for this protein. In the major-
ity of normal tissue and benign lesions, < 10% of non-
basal keratinocytes were positive for p53. In CIS and
SCCs, 10 to 90% of non-basal cells were positive for p53
(Table 2, Fig. 3 and Additional file 3: Figure S3).
In most of the lesions and normal perilesional tissue,
> 10% of basal cells and < 10% of non-basal cells exhib-
ited nuclear Ki67 expression. In two of three CIS how-
ever, Ki67 expression was more pronounced (> 10%).
Unexpectedly, two SCCs appeared negative for this pro-
liferation marker in the majority of the assessed fields
(Table 2, Fig. 3 and Additional file 4: Figure S4).
Over 90% of basal cells in all tissues were positive for
nuclear MCM7 immunostaining. In almost all normal
perilesional tissues < 10%, and in most hyperplasias <
50% of non-basal cells expressed this protein. In SCCs,
CIS and most papillomas, 10–90% of non-basal cells
were positive for MCM7, depending on the degree of
differentiation within the lesions (Table 2, Fig. 3 and
Additional file 5: Figure S5).
MMP1-immunostaining of tissue sections yielded a
diffuse cytoplasmic signal that was neither tumour- nor
cell differentiation-specific and, therefore, was non-
discriminatory (not shown).
Discussion
Proposal for histological classification of EcPV2-associated
lesions
In horses SCC is reported to be the most common neo-
plasm of the external male genitalia [6, 21, 22]. It is sug-
gested that the gross description plaques and wart-like
lesions (papillomas) represent precursor lesions of this
malignant tumour type [10, 21, 22]. However, this study
shows, that plaques as well as wart-like lesions can
already represent CIS i.e. malignant lesions preceding in-
vasive SCCs and thus requiring more aggressive therapy.
Therefore the histological analysis is very important in
these lesions. However, gross and histological descrip-
tions of these precursor lesions vary considerably in the
literature [6, 10, 23–25]. When reassessing H&E-stained
sections of equine penile lesions in this study, it was
Table 2 RISH and marker screening results in all samples
ID Diagnosis EcPV2 RISH p53 MCM7 Ki67
GS DNS b nb b nb b nb
1 SCC (G3) pos 2 3 2 4 3 1 1
2 SCC (G2) pos 4 4 3 4 2 0 0
3 SCC (G3) pos 7 4 2 4 2 2 1
4 early SCC (G3) pos 0 4 2 4 2 0 0
5 early SCC (G3) pos 3 4 3 4 3 3 1
6 CIS pos 1 4 3 4 3 3 2
7 CIS (pos) 0 4 3 4 2 2 1
8 CIS (pos) 0 2 2 4 3 2 2
9 Papilloma pos 27 4 1 4 3 1 1
10 Papilloma pos 0 4 1 4 2 3 1
11 Papilloma pos 69 4 2 4 4 3 2
12 Papilloma pos 8 4 1 4 2 2 1
13 Papilloma pos 14 4 1 4 3 2 1
14 Hyperplasia pos 98 2 1 4 1 1 1
15 Hyperplasia pos 72 3 1 4 2 2 1
16 Hyperplasia pos 27 2 1 4 2 2 1
17 Hyperplasia pos 84 2 1 4 2 3 1
18 Hyperplasia pos 7 4 1 4 2 2 1
19 Hyperplasia pos 49 4 2 4 1 2 1
9a normal adjacent skin neg 0 2 1 4 1 1 0
12a normal adjacent skin neg 0 3 2 4 1 1 1
14a normal adjacent skin neg 0 2 1 4 2 2 1
15a normal adjacent skin neg 0 3 2 4 1 2 1
16a normal adjacent skin neg 0 2 1 4 1 2 1
Pos: positive; (pos): weak positive, neg: negative; b: basal layer; nb: non-basal
layers; 0: negative; 1: < 10% of cells positive; 2: 10–50% of cells positive; 3: 51–
90% of cells positive; 4: > 90% of cells positive
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evident that the histological diagnosis varied among pa-
thologists of the different institutions. This is likely due
to the lack of a consistent and widely approved histo-
logical classification for EcPV2-associated equine penile
lesions.
In humans, diagnosis of penile precancerous lesions
and invasive carcinomas is likewise challenging [11].
Given that human penile precursor lesions and SCCs
closely resemble their equine counterpart [7, 26], this
study attempted to categorize EcPV2-associated equine
penile lesions based on human data [9] and descriptions
of equine disease [6, 10, 23–25] in order to obtain well
defined histological classes regardless of their clinical
appearance.
Fig. 2 H&E staining and EcPV2 RISH signal distribution in penile lesions. One representative example per lesion (perilesional epithelium #14a,
hyperplasia #14, papilloma #12, CIS #6 and SCC #5) is shown. a and b: H&E stained sections photographed using 2x (a) and 20x objectives (b). c
and d: RISH stained sections photographed using 2x (c) and 40x (d) objectives. White squares in panel a and c mark the enlarged area shown in
panel b and d. Perilesional skin: Squamous epithelium with normal maturation (a and b) and numerous pigmented cells in the basal layer (b). No
viral signal is detectable in perilesional skin (c and d). Benign hyperplasia: Thickening of the epithelium and formation of broad rete ridges (a).
There is orderly maturation and presence of koilocyte-like cells (white arrows) (b). Strong RISH signal is detectable, consisting of diffuse nuclear
staining (DNS) (black arrows), which is detectable also at low magnification (c and d). The nuclear and cytoplasmic granular staining (GS) (small
red dots in almost all lesional cells) is just visible at high magnification (d). Papilloma: Finger-like projection of moderately hyperplastic, mildly
hyperkeratotic stratified squamous epithelium with normal differentiation and thin central cores of connective tissue (a and b). EcPV2 RISH
staining in this case included mild DNS (c) and strong GS (d). CIS: Transepithelial mildly disrupted epithelial maturation can be seen (a and b).
The keratinocytes show increased variability of keratinocytes and mitotic figures in the suprabasal region can be noted (white arrows b). There is
intra-epithelial keratin pearl formation (white arrow a). EcPV2 RISH GS is just detectable at 40x magnification and no DNS is present (c and d).
SCC: Infiltrating islands and trabeculae of moderately differentiated squamous epithelium with keratin pearl formation, (white arrows a). The
keratinocytes are highly variable, show numerous mitotic figures (white arrows) and some cells are keratinized (black arrow) (b). The EcPV2 RISH
DNS is rarely detectable within the infiltrating islands (c), while strong GS can be noticed (d)
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Thickening of the epithelium with orderly matur-
ation accompanied by the formation of broad rete
ridges corresponds to a (benign) hyperplasia as de-
scribed by Chaux et al. [9]. In the equine literature the
same features are sometimes attributed to papillomas
in horses [6, 27]. Lesions with crowding of basal cells
or small intraepithelial keratin pearls were included,
because these alterations were considered to be dys-
plastic rather than neoplastic. Chaux et al. [9] use the
term differentiated penile intraepithelial neoplasia
(PIN) for such changes (with crowding of basal cells
and/or intra-epithelial keratin pearls), whereby the
specification “differentiated” implies a still benign,
presumably non-neoplastic character of the change,
which is why these two groups of lesions (hyperplasia
and differentiated PIN) were combined in the present
study.
The neoplastic alteration CIS can be distinguished by
abnormal transepithelial maturation, increased variability
of keratinocytes and frequent presence of mitotic figures
in the suprabasal region. This description aligns with pre-
vious descriptions of equine penile CIS [24, 28] as well as
with Chaux et al. [9] who refers to this change as a dedif-
ferentiated PIN, indicating the increasingly malignant
Fig. 3 p53, MCM7 and Ki67 immunostaining of penile lesions. One representative example per type of lesion (perilesional normal epithelium
#14a, hyperplasia #14, papilloma #12, CIS #6 and SCC #3) is represented. p53, MCM7 and Ki67 immunostaining was photographed using the 10x
objective. p53 immunostaining in perilesional epithelium and hyperplasia is restricted mainly to the basal layer with nuclear labelling of few/
single cells. In papilloma, CIS and SCC almost all basal cells express p53. However, in CIS and SCC p53 expression extended to the upper
suprabasal layers and was enhanced. MCM7 is expressed in almost all basal cells within all lesional and perilesional tissue samples. In CIS and SCC,
MCM7 is also expressed in upper suprabasal layers of the epithelium. Ki67 was restricted mainly to the basal layer with nuclear labelling of few/
single cells of perilesional epithelium, hyperplasia and papilloma. In malignant lesions Ki67 expression was increased and extended to upper
suprabasal layers
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character. In the present study two CIS lesions had very
small, solitary areas with a few cells focally disrupting the
basement membrane, suspected to represent areas of
microinvasion. This observation does not warrant a diag-
nosis of SCC, which should infiltrate profusely (over a
large area, broadly) and not only in a very small area, but
highlights the dynamic character and progressive potential
of disease. To the best of our knowledge microinvasion is
not mentioned in the equine literature on penile precursor
and cancerous lesions. It is controversially discussed in re-
gard to human cancerous lesions and rarely mentioned in
the literature on penile carcinomas in man [9, 29, 30].
Chaux et al. [9] describes microinvasion in a differentiated
PIN without then classifying the change as SCC.
Papillomas were diagnosed when finger-like projec-
tions of thickened, usually mildly hyperkeratotic squa-
mous epithelium with normal maturation and thin
central cores of connective tissue were present. This type
of benign neoplastic lesion is not frequently mentioned
in the literature and most closely corresponds to the
papillomas described by Suarez-Bonnet et al. [26] and
the fibropapillomas described by Lange et al. [24],
whereas the papillomas described by Knight et al. [27]
and van den Top et al. [6] more closely fit into our cat-
egory of benign hyperplasia.
Lesions classified as SCCs contained infiltrative islands
and trabeculae of squamous epithelial cells with or without
keratinization originating from the epithelium and infiltrat-
ing profusely the underlying dermal tissue in accordance
with van den Top, 2011 [10]. This study distinguishes be-
tween early invasive forms and late invasive forms, a dis-
tinction that is not normally found in the equine literature.
Early invasive tumours (with limited infiltration of the sub-
epithelial tissue) most likely represent an early stage of
SCC. This information can be important for a clinician
when deciding whether to choose a more aggressive or less
aggressive therapeutic approach. SCCs were graded accord-
ing to van den Top et al. [10] because prognosis is related
to tumour grade. SCC can be heterogeneous and the poor-
est differentiated area determines the grade [20]. Most tu-
mours of the present study were heterogeneous as
described by others [10, 31] and consist of moderately as
well as poorly differentiated areas and were therefore classi-
fied as grade 3. Interestingly, the only grade 2 SCC was de-
scribed clinically as wart-like lesion, while the grade 3 SCCs
were described clinically as tumoural lesions of larger sizes.
However, since no follow-up information is available for
the SCCs of this study and the number of cases is small, no
further interpretation can be made.
Aetiological association of EcPV2 with equine penile SCCs
and precursor lesions based on PCR and RISH
As anticipated on the basis of previous reports reviewed
by Sykora et al. [4] all lesions tested positive for EcPV2
DNA as revealed by virus type-specific PCR. Since there
are other papillomaviruses described to be associated
with equine genital lesions, and co-infections with other
PVs were reported [32–34], also broad-range PV PCR
using CP4/5 [35] and Fap 59/64 [36] primer sets was
done to detect other potentially involved PVs. These
primers are designed to also detect the equine PVs type
3–8 [32–34, 37] and the sarcoid associated bovine PVs
type 1 and 2 [38]. Using these two broad-range PV pri-
mer sets, no other PVs were detectable, hence it is not
likely that other PVs were involved in the development
of the lesions assessed in this study. However, due to the
lower sensitivity of broad-range primers compared to
specific primers and the potential involvement of papil-
lomaviruses which are not detectable by this primer sets,
it cannot be excluded that other PVs play a role in some
of these lesions. Nevertheless, it appears that EcPV2 is
one of the main factors involved in the development of
equine genital lesions, as it was detectable in all equine
genital lesions assessed in this study.
Lesions were assessed also by EcPV2 E6/E7 RNA in
situ hybridization (RISH) [39] to detect and localize viral
nucleic acids. Of note, EcPV2 RISH recognizes both E6/
E7 DNA and mRNA, possibly explaining the two differ-
ent types of signal (GS and DNS) yielded by the method.
Interestingly, RISH signal patterns analogous to those
observed here in the EcPV2-associated equine genital le-
sions have been detected with hrHPV-associated neo-
plasms as well [40, 41]. Previous studies support the
concept that DNS can be attributed to the presence of
both papillomaviral RNA and DNA [12, 41]. One study
proposed that DNS may result from probe hybridization
with ‘unzipped’ single-stranded HPV-DNA, which oc-
curs during episome synthesis in the productive phase of
the HPV life-cycle. In that study, the authors proposed
that RISH could be used for grading HPV-associated
cervical intraepithelial neoplasia (CIN1–3) lesions, as
CIN1 lesions exhibit abundant DNS, while CIN3 lesions
exhibit little to no DNS in the transformative phase [12].
Similarly, in the present equine study benign lesions had
a high level of DNS, suggestive of a productive EcPV2
life cycle, while CIS and SCC had a low level of DNS, as
expected for transformative processes.
Importantly, histological reassessment of some lesions,
which have previously been macroscopically interpreted
as (benign) plaques, led to a diagnosis of CIS. The abun-
dance of DNS helped distinguishing these malignant le-
sions from benign hyperplasia and is thus proposed as
an adjuvant diagnostic marker. These findings also make
clear that plaques do not necessarily represent early be-
nign lesions and thus require careful diagnosis and cor-
responding treatment.
In this study 100% of lesions exhibited GS in accord-
ance with EcPV2 PCR results. The perilesional normal
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skin surrounding the assessed lesions, if present on the
same slide, was negative for EcPV2 RISH. It is known
that EcPV2-DNA can also be detected in healthy horses
with a prevalence between 1 and 18% in different studies
[22, 42, 43], and that subclinical infections also might
get cleared by the immune system, as up to 15–36% of
healthy horses have antibodies against EcPV2 as well
[42, 44]. However, looking at the results obtained in this
study, it seems that if the horses develop lesions, this oc-
curs exclusively in EcPV2 infected and transcriptionally
active areas but not in EcPV2 negative areas. This find-
ing further supports the concept that EcPV2 infection
has an active role in tumour onset and progression [4].
In summary, RISH can be used to detect and localize
EcPV2 RNA/DNA in FFPE tissue samples. The different
signal distribution patterns and amount of DNS might
help to distinguish between early proliferative and late
progressive tumour stages, as the amount of DNS sig-
nificantly differed between benign and malignant lesions.
IHC-based marker gene expression in different lesions
p53 has a critical role in cell cycle regulation and is in-
volved in cell cycle arrest, DNA repair and apoptosis
[45]. In approximately 50% of human tumours, the p53
gene is mutated. Mutations within the p53 gene fre-
quently compromise the tumour-suppressive activity of
the corresponding protein, thus promoting tumour onset
and progression [13]. In contrast to wild-type p53, which
is an unstable protein with a short half-life, mutant p53
can accumulate within tumour cells, thus representing a
potential tumour marker [46]. p53 immunopositivity has
also been shown to strongly correlate with p53 muta-
tional status [47]. However, anti-p53 antibody usually
recognizes both accumulated wild-type and mutated
forms of the protein [46]. This fact explains why the use
of p53 as human cervical cancer marker is controversial
[13]. In human penile SCCs however, strong nuclear p53
immunostaining has been consistently detected, in con-
trast to adjacent normal perilesional skin, which has a
moderate to weak signal mainly confined to the basal
layer [48]. In addition, p53 immunostaining can be used
to distinguish human penile intraepithelial lesions from
squamous hyperplasia [49] and p53 expression levels in
human penile carcinomas may have prognostic value in
predicting lymph node metastasis and survival [50]. In
an equine study on penile lesions it was already shown,
that expression of p53 increases with decreased differen-
tiation of the tumour, but could not be used as prognos-
tic factor for metastatic disease [20]. In the present
equine study, lesional and histologically normal perile-
sional tissue were positive for p53. Given that, to date,
equine p53 has not been assessed for mutations in the
context of penile tumour disease, it is unclear whether
wild-type and/or mutant p53 are detected by IHC.
Nonetheless, p53 expression by basal cells of most SCCs,
CIS and papillomas (> 90%), markedly differed from that
of most hyperplasia and normal perilesional tissue (<
50%). Within the non-basal layers, < 10% of cells were
positive for p53 in most perilesional, hyperplastic and
papilloma tissues, while distinctly more non-basal cells
expressed p53 in CIS and SCCs (10–90%). Consequently,
assessing the number and locations of p53-positive cells
within equine penile lesions might help to distinguish
between benign and malignant lesions.
Ki67 is widely used in routine tumour assessment as a
prognostic and predictive indicator [51]. In human cer-
vical lesions, Ki67-staining is used for the grading of
progressive cervical tumours [13]. In human penile can-
cer, Ki67 expression is correlated with tumour grade, al-
though it has no prognostic value [52]. Based on this,
the hypothesis of this study was that Ki67 may represent
a potential diagnostic marker in horses. However, Ki67
staining of equine penile lesions yielded inconsistent re-
sults, with two SCCs appearing almost negative for this
proliferation marker. Standardized tissue sample hand-
ling may be an important prerequisite for accurate as-
sessment of the Ki67 index. Using the same Ki67
antibody, it was shown that insufficient, delayed and
prolonged fixation can have a negative effect on Ki67
antibody binding [53]. The two negative/weak SCC sam-
ples were received from Germany and had both a pro-
longed fixation time, which might explain these results.
When collecting horse samples from different regions,
these procedures cannot always be standardized. Conse-
quently, Ki67-staining cannot be recommended for diag-
nosis and lesion assignment of EcPV2-associated equine
penile lesions. This is also supported by another study
using this antibody in equine penile and preputial SCCs
whereby they could also not find expression differences
between different subtypes [20]. The proliferation
marker MCM7 is more sensitive in detecting cycling
cells than Ki67 in humans and dogs and therefor might
be superior to Ki67 as a proliferation marker [54–56].
High expression of MCM7 can serve as a predictive
biomarker for poor prognosis in human cancers [57].
In hrHPV-induced high-grade lesions, MCMs are
over-expressed and serve as established surrogate
markers for papillomaviral E6/E7 oncoprotein activity
[14]. In particular MCM7 constitutes a reliable human
cervical cancer marker. In normal and benign hyper-
plastic cervical tissue, MCM7 expression is restricted
to basal and immediate para-basal layers, while full
thickness immunostaining is observed in high grade
cervical dysplasia and invasive cancers [58]. In the
present study, lesional as well as normal perilesional
basal keratinocytes expressed MCM7, as expected on
the basis of human data. In non-basal keratinocyte
layers, MCM7 expression was most often increased in
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papillomas, CIS and SCCs, depending on the degree of
differentiation within the lesions. In non-differentiated
parts of the lesions, cells appeared to be still prolifer-
ating and express MCM7 in higher levels, than in
more differentiated parts of the lesion. In human cer-
vical cancer, MCM expression is thought to depend
on hrHPV E7 expression, which results in the inactiva-
tion of pRB and the related proteins p107 and p130.
This in turn activates the E2F family of transcription
factors and thereby induces expression of E2F-
responsive genes such as MCMs [58]. Interestingly,
the EcPV2 E7 open reading frame lacks a pRB binding
domain [3, 4]. Hence, the mechanisms by which
EcPV2 infection promotes MCM7 expression by non-
basal cells remains unclear. Importantly, it has been
shown that HPV16 can likewise induce E2F responsive
genes - especially MCM7 - in the absence of E7 in re-
productive epithelia and tumours [59]. In analogy, it
can be speculated that MCM7 expression in upper
keratinocyte layers of progressive penile lesions may
be driven by EcPV2 E6. The RISH data generated in
the present equine study do not fully support this pos-
sibility, as MCM7 expression and signals obtained by
E6/E7 RISH did not always colocalize. In humans,
MCM7 expression is also seen in HPV-negative penile
cancers, suggesting that MCM7 expression may de-
pend on the amount of proliferating cells within the
lesions and not entirely on the papillomaviral onco-
proteins E6 and E7 [60]. Gene expression profiling of
EcPV2-associated equine genital cancer has shown a
strong up-regulation of MCM transcripts [8]. In the
present study, this finding has been confirmed on the
protein level. Evaluation of MCM7 expression in
upper epithelial layers may therefore help to distin-
guish well-differentiated equine penile lesions from
less-differentiated, more proliferative lesions.
MMP1 transcription was recently shown to be upregu-
lated in EcPV2-associated genital SCCs [8], and over-
expression of this proteinase has been previously demon-
strated to correlate with progression of bovine PV-
induced equine sarcoids [17, 18]. However, in the present
study MMP1-immunostaining of equine penile lesions
yielded a diffuse cytoplasmic signal throughout the differ-
ent cell layers of all samples, disqualifying MMP1 IHC or
the staining protocol applied in the present study as a use-
ful technique for investigation of EcPV2-associated penile
lesions.
Conclusions
Histological diagnoses of equine penile SCC precursor
lesions are challenging since no consistent or validated
classification system exists. In this study, histological cri-
teria that allow for a more precise, and hence more con-
sistent diagnosis of penile hyperplasias, papillomas, CIS
and SCC, were developed and proposed. Importantly, it
was also demonstrated that the general term ‘plaque’ is
not synonymous with benign hyperplasia, as it may also
describe CIS. Assessment of lesions for genomic EcPV2
sequences and transcripts proved useful for the discrim-
ination of SCCs and associated precursor lesions from
other penile tumour types such as sarcoids and melano-
mas and may help to distinguish between early prolifera-
tive and late progressive tumour stages. In addition, p53-
and MCM7-immunostaining may provide additional
information on the severity of a lesion as it may facilitate
the distinction of benign lesions from more progressive
EcPV2-associated penile tumours.
Methods
Sample material
The databases of the Institute of Veterinary Pathology of
the Vetsuisse Faculty University of Zurich and the Institute
of Animal Pathology of the Vetsuisse Faculty University of
Bern were searched for penile SCC precursor lesions and
SCCs. Sixty-one H&E-stained tumour sections were re-
trieved and histologically reassessed by microscopy. Follow-
ing histological analysis, 19 representative snap-frozen and/
or paraffin-embedded tumour samples diagnosed as benign
hyperplastic lesions (n = 6), papillomas (n = 5), CIS (n = 3)
and SCCs (n = 5) were chosen for further assessment in this
study. Age, breed, clinical description from the referring cli-
nicians and histological diagnosis of the included horses are
shown in Table 1. It should be noted that in some horses
more lesions were present simultaneously, while the lesion
assessed in this study is marked in bold in Table 1. From
one horse with an ulcerative lesion on the penis shaft and
papillomas on shaft and glans penis, both lesions were in-
cluded in this study and listed as separate cases (#5, #13).
The images from perilesional normal skin were taken from
five horses with papilloma or hyperplasia (# 9, #12, #14,
#15, #16), which are also included in the study. In these
cases also normal skin was present on the same slide.
Therefore, the samples from normal adjacent skin were
numbered as #9a, #12a, #14a, #15a and #16a (Table 1).
PCR-based assessment of lesions for the presence of PV
DNA
Total DNA was extracted from ±2mm3 native, or 3 × 30
μm paraffin-embedded tumour specimens using a QIAamp
DNA Minikit or QIAamp DNA FFPE Tissue Kit following
the manufacturer’s instructions (Qiagen, Hilden, Germany).
PCR-compatibility of extracted DNA was successfully con-
firmed by equine GAPDH PCR as described previously
[33]. Subsequently, DNA aliquots were subjected to
EcPV2-specific PCR using an EcPV2 specific primer set
(E6-41f /E6–435) for amplification of the E6 gene (position
41–435) [3]. To assess whether also other PVs are present
in those lesions, two other broad-range PV PCR reactions
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using the primer sets CP4/5 and Fap59/64 were [35, 36]
analysed. Reactions were performed in 25 μl-volumes, con-
taining 12 μl of REDTaq ReadyMIX (Sigma-Aldrich; Merck
KGaA, Darmstadt, Germany), 8 μl of water, 2 μl of each for-
ward and reverse primer (10 μM each) and 1 μl of extracted
DNA as template. The cycling program consisted of a de-
naturation step of 3min at 94 °C, followed by 40 cycles of
30 s at 94 °C, 30 s at 55 °C (ecGAPDH and EcPV2) or 42 °C
(CP4/5 and FAP59/64) and 30 s at 72 °C. Then, amplicons
were analysed by 1% TAE-gel electrophoresis and visualized
by GelRed® Nucleic Acid Gel staining (Biotium; VWR
International AG, Dietikon, Switzerland).
RISH-based assessment of lesions for the presence and
localization of EcPV2 E6 and E7 transcripts
Presence and localization of EcPV2 transcripts were
assessed by E6/E7 RNA in situ hybridisation (E6/E7
RISH) according to Zhu et al. [41]. RISH was run on all
FFPE tissue samples in replicates (5 per lesion) using the
RNAscope 2.5 HD Detection Kit RED according to the
manufacturer’s instructions (Advanced Cell Diagnostics,
Newark, NJ, USA) with minor modifications: Xylene
Substitute (Sigma-Aldrich) was used instead of xylene;
slides were placed into boiling 1x target retrieval solu-
tion for 15 min to expose nucleic acids; counterstaining
was performed in 20% instead of 50% haematoxylin
(Sigma-Aldrich).
According to observed hybridisation patterns, distinc-
tion was made between a finely scattered GS throughout
the nucleus and cytoplasm, and an intense DNS filling
the entire nucleus (Fig. 1b). Lesions were classified as
RISH-positive when GS-positive keratinocytes were de-
tected by screening of ten high magnification fields (40x
objective). The presence and number of DNS-positive
cells were evaluated by counting in five low magnifica-
tion fields (4x objective). The mean number of DNS-
positive cells per field was evaluated and used to com-
pare early (benign hyperplasia, papilloma) with advanced
stages of disease (CIS and SCC). To determine the
statistical significance of observed differences, a two-
tailed Mann Whitney test using GraphPad Prism 7
(GraphPad Software, San Diego, CA, USA) was carried
out.
Immunohistochemical analysis of tumour sections for
p53, Ki67, MCM7 and MMP1 expression
Five 3.5-μm sections per lesion were prepared from paraffin-
embedded tissue and placed on positively charged glass
slides. Immunohistochemical (IHC) staining was performed
using an automated staining device (Dako Autostainer; Dako
Schweiz GmbH, Basel, Switzerland) with diaminobenzidine
(DAB) or 3-Amino-9-ethylcarbazole (AEC) (both from
Dako) serving as chromogen and Meyer’s haematoxylin as
counterstain. Negative controls were generated by omitting
the primary antibody. Detailed incubation conditions for
each antibody (anti-p53, −MCM7, −Ki67 and -MMP1) and
respective providers are given in Table 3. For scoring pur-
poses, the number of immunopositive cells in the basal cell
layer was counted (if crowded, the next 1–2 layers were in-
cluded) and percentages calculated. Using the same tech-
nique, the number of immunostained cells in the non-basal
layers was also evaluated. The following scores (0–4) were
assigned to calculated percentages of immunopositive cells:
0% = 0, < 10%= 1, 10–50%= 2, 51–90%= 3, > 90%= 4. Ten
fields per tumour section were evaluated using the 10x ob-
jective and the mean scores per section calculated as repre-
sented by Fig. 1. Normal perilesional regions within tissue
sections served as additional internal negative controls.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12917-019-2097-0.
Additional file 1: Figure S1. H&E staining in all samples. One
representative H&E staining image photographed using 4x objectives of
each sample used in this study are shown (#1–3 SCC, #4, #5 early SCC,
#6–8 CIS, #9–13 Papilloma, #14–19 Hyperplasia, #9a, #12a, #14a, #15a and
#16a normal adjacent skin).
Table 3 IHC antibody specifications
Primary antibody Use Retrieval 2nd antibody Chromogen Control
Monoclonal mouse
anti-Ki67 (clone MIB-1;
Dako)
1:50
1 h, RT
98 °C; pH 9 REAL kit
(Dako, K5007)
AEC Equine skin,
rectum
Monoclonal mouse
anti-p53 (clone DO1;
Santa Cruz)
1:100
1 h, RT
98 °C; pH 9 Envision mouse
(Dako, K4001)
DAB Equine SCC
Monoclonal mouse
anti-MCM7 (clone DCS-
141.2; Santa Cruz)
1:400
1 h, RT
98 °C; pH 9 Envision mouse
(Dako, K4001)
DAB Equine lymph
node
Polyclonal rabbit
anti-MMP1
(ThermoFisher)
1:50
O/N, 4 °C
98 °C; pH 7 Envision rabbit
(Dako, K4003)
DAB Equine SCC
RT Room temperature, O/N overnight, AEC Aminoethylcarbazol, DAB Diaminobenzidine
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Additional file 2: Figure S2. RISH signal distribution in all samples. One
representative RISH stained image photographed using 4x objectives of
each sample used in this study are shown (#1–3 SCC, #4, #5 early SCC,
#6–8 CIS, #9–13 Papilloma, #14–19 Hyperplasia, #9a, #12a, #14a, #15a and
#16a normal adjacent skin).
Additional file 3: Figure S3. p53 immunostaining in all samples. One
representative p53 immunostaining image photographed using 4x
objectives of each sample used in this study are shown (#1–3 SCC, #4, #5
early SCC, #6–8 CIS, #9–13 Papilloma, #14–19 Hyperplasia, #9a, #12a, #14a,
#15a and #16a normal adjacent skin).
Additional file 4: Figure S4. Ki67 immunostaining in all samples. One
representative Ki67 immunostaining image photographed using 4x
objectives of each sample used in this study are shown (#1–3 SCC, #4, #5
early SCC, #6–8 CIS, #9–13 Papilloma, #14–19 Hyperplasia, #9a, #12a, #14a,
#15a and #16a normal adjacent skin).
Additional file 5: Figure S5. MCM7 immunostaining in all samples.
One representative MCM7 immunostaining image photographed using
4x objectives of each sample used in this study are shown (#1–3 SCC, #4,
#5 early SCC, #6–8 CIS, #9–13 Papilloma, #14–19 Hyperplasia, #9a, #12a,
#14a, #15a and #16a normal adjacent skin).
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